Afanix 40 mg

Generic Name: Afatinib
Brand: Afanix
Strength: 40 mg
Manufacturer: Beacon Pharmaceuticals Ltd.

Indications:

Afanix 40 mg (Afatinib) is indicated for the treatment of patients with non-small cell lung cancer (NSCLC) that is epidermal growth factor receptor (EGFR) mutation-positive. It is also used in metastatic NSCLC patients who have not previously received an EGFR tyrosine kinase inhibitor therapy.

Pharmacology:

Afatinib is an irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4). By binding covalently, it blocks the signal transduction pathways responsible for the growth and spread of cancer cells, resulting in tumor regression.

Dosage & Administration:

The recommended dosage of Afanix is 40 mg orally once daily, taken at least 1 hour before or 2 hours after a meal. Dose adjustments may be required based on patient tolerance and adverse reactions.

Contraindications:

• Known hypersensitivity to Afatinib or any component of the product.

• Use with caution in patients with severe hepatic or renal impairment.

Side Effects:

Common side effects include:

• Diarrhea

• Rash or acne

• Stomatitis

• Paronychia (nail infection)

• Dry skin

• Decreased appetite

Pregnancy & Lactation:

Afatinib may cause fetal harm when administered during pregnancy. It is not recommended during pregnancy or breastfeeding unless absolutely necessary.

Precautions & Warnings:

• Monitor liver function and renal function regularly.

• Use with caution in elderly patients.

• Ensure proper hydration to minimize risk of dehydration due to diarrhea.

Overdose Effects:

There is no specific antidote. In case of overdose, supportive care should be provided. Monitor for adverse reactions, especially gastrointestinal symptoms.

Therapeutic Class:

• Anticancer drugs

• EGFR Tyrosine Kinase Inhibitors (TKIs)

Storage Conditions:

• Store below 30°C, in a dry place, protected from light and moisture.

• Keep out of reach of children.